FindTrial
Sign In

Randomised, double-blind, placebo controlled, study to evaluate the safety and efficacy of acetyl L-carnitine (ALCAR), in combination with antiretroviral therapy, for prevention of distal symmetric polyneuropathy (DSP) and lipid abnormalities in treatment of human immunodeficiency virus (HIV)

Randomised, double-blind, placebo controlled, study to evaluate the safety and efficacy of acetyl L-carnitine (ALCAR), in combination with antiretroviral therapy, for prevention of distal symmetric polyneuropathy (DSP) and lipid abnormalities in treatment of human immunodeficiency virus (HIV)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN58811572
Enrollment
40
Registered
2005-09-30
Start date
2002-11-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distal symmetric polyneuropathy (DSP) Nervous System Diseases Other polyneuropathies

Interventions

Randomised controlled trial

Sponsors

Department of Health
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 40 patients

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Primary endpoint: the change in baseline in total area of PGP (protein gene product) immunostaining on the epidermis at 48 weeks—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026